MetabERN

What MetabERN does

MetabERN is a European Reference Network (ERN) dedicated to inherited metabolic diseases (IMDs), established in 2017 as one of 24 ERNs approved by the ERN Board of Member States and funded by the European Commission. The network coordinates clinical care, knowledge exchange, and research across 94 specialised healthcare centres in 28 European countries, engaging more than 3,000 healthcare professionals and 39-46 patient organisations. Its core constituency consists of patients with rare metabolic disorders and the specialised clinicians who treat them, with a Patient Board providing structured representation of patient voice in governance.

The network's core technology platforms include the Clinical Patient Management System (CPMS), a virtual consultation platform enabling cross-border expert opinions on challenging IMD cases, and the U-IMD (Unified European Registry for Inherited Metabolic Disorders), which serves as the network's official patient registry. Clinical operations are organised into seven disease-specific subnetworks covering pyruvate metabolism/mitochondrial disorders (PM-MD), aminoacid/organic acidurias (AOA), lysosomal storage disorders (LSD), carbohydrate/fatty acid oxidation disorders (C-FAO), peroxisomal disorders (PD), congenital disorders of glycosylation (CDG), and neuromodulators/small molecules (NOMS). Supporting assets include the DCTEP e-learning programme, an Emergency Protocol Tool, a Newborn Screening coordination programme, the Knowledge Hub, and the 2025-2027 Healthcare Professional Exchange Programme.

MetabERN is a non-profit, non-commercial entity funded by European Commission grants via the ERN programme. Revenue is not publicly disclosed and services are not priced for individual patients; rather, the network operates as a coordination layer across publicly funded European healthcare provider institutions. The coordination office is hosted at Azienda Sanitaria Universitaria Friuli Centrale in Udine, Italy, with approximately 6 staff. Distribution is through the 94 member centres and 46 patient organisations, supplemented by national hubs, an annual board meeting, scientific symposia (including SSIEM Annual Symposium collaboration), and digital channels such as the website, newsletter, and social media.

Name

MetabERN

Legal name

MetabERN

Website

https://metab.ern-net.eu

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

MetabERN is a European Reference Network, established in 2017 and funded by the European Commission, that coordinates care, research, and education for inherited metabolic diseases across 94 specialised centres in 28 countries, serving rare disease patients and clinical specialists.

Ownership category

akta.pro rank

Product category

Rare Disease Healthcare Network

NAICS

Other Individual and Family Services (624190)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

HIE Platforms & Network Services (Community/Regional/National) (HLACABAB)

akta.pro secondary industries

Health Information Exchange & Public Health Data Integration (HLAJAJAD), Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE) (HLACABAA), Public Health Genomics & Sequencing (WGS/Metagenomics) Networks (HLAJAIAK)

Keywords

• Rare disease networks
• Inherited metabolic disorders
• Cross-border healthcare
• Clinical reference networks
• Metabolic disease research

Headquarters

HQ city

Udine

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. European Commission Funding: MetabERN is funded by the European Commission as part of the European Reference Networks initiative. The ERNs were launched in 2017 with EU support, involving over 900 highly specialised healthcare teams in more than 300 hospitals.

Distribution channels4 records

Marketing channels9 records

Core offering

MetabERN is a European Reference Network that connects 94 specialised healthcare centres across 28 European countries to facilitate cross-border diagnosis, treatment, and research for inherited metabolic diseases (IMDs). Its core offerings include the CPMS virtual consultation platform, the U-IMD patient registry, the DCTEP e-learning programme, disease-specific subnetworks, clinical guidelines, and an Emergency Protocol Tool, all coordinated with a Patient Board of patient organisations.

Product overview

MetabERN is a European Reference Network (ERN) for Inherited Metabolic Disorders, established by the EU in 2017 as one of 24 ERNs. It is not a traditional software product company but rather a healthcare network connecting 94 specialized centres across 28 European countries, with over 3000 healthcare professionals and 46 patient organisations. The network provides a platform for exchange of best practices, clinical guidelines development, and cross-border healthcare facilitation. MetabERN's core offerings include the U-IMD patient registry (Unified European Registry for Inherited Metabolic Disorders), the CPMS virtual consultation system for expert consultations, and the DCTEP e-learning education programme. The network is organized into 7 disease-specific subnetworks covering pyruvate metabolism (PM-MD), aminoacid/organic acids (AOA), lysosomal storage disorders (LSD), carbohydrate/fatty acid oxidation (C-FAO), peroxisomal/lipid-related disorders (PD), congenital disorders of glycosylation (CDG), and neuromodulators/small molecules (NOMS). Additional services include newborn screening programmes, emergency protocols, patient resources, and the Knowledge Hub for educational materials.

Differentiator

Problem solved

Functional benefit

Products and services

• U-IMD Registry (Unified European Registry for Inherited Metabolic Disorders) Unified European patient registry for inherited metabolic disorders that enables standardised data collection, clinical research, and outcome tracking across MetabERN's 94 member centres.
• Clinical Patient Management System (CPMS) Virtual consultation platform that enables healthcare professionals across MetabERN's member centres to collaborate on challenging inherited metabolic disease cases via cross-border expert panels.
• DCTEP (Diagnostic, Clinical and Therapeutic Education Programme) E-learning course on inherited metabolic disorders providing diagnostic, clinical, and therapeutic education to healthcare professionals across Europe.
• Knowledge Hub Online resource hub providing access to clinical guidelines, educational materials, and informative resources for healthcare professionals and patients in inherited metabolic diseases.
• Online-Inherited Metabolic Disease Platform Online educational platform offering courses and training materials on inherited metabolic diseases for clinicians and other learners.
• Emergency Protocol Tool Tool providing emergency protocols for managing metabolic crises in inherited metabolic disorders, supporting rapid clinical decision-making in acute settings.
• Newborn Screening Programme Programme focused on newborn screening for inherited metabolic disorders across European member states, supporting early diagnosis and care pathways.
• Cross-border Healthcare Services Services facilitating access to specialised healthcare across EU member states for patients with rare metabolic diseases, operationalised through the EU Cross-Border Healthcare Directive.
• Patient Journeys and Clinical Care Pathways Documented patient care pathways and clinical workflows for inherited metabolic disorders, designed to standardise diagnosis and treatment across MetabERN member centres.
• MetabERN Exchange Programme (2025-2027) Structured exchange programme enabling healthcare professionals to rotate between MetabERN member centres across Europe for cross-border training and knowledge exchange from 2025 to 2027.

Quantifiable outcome

• 94 specialised centres across Europe
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• European CommissioncoreStrategic or Co-development Partner · 1 January 2017MetabERN is approved by the ERN Board of Member States and funded by the European Commission. The ERNs were launched in 2017 involving more than 900 highly specialised healthcare teams in more than 300 hospitals across 28 European countries.
• Azienda Sanitaria Universitaria Friuli CentralecoreStrategic or Co-development PartnerH ospital hosting the MetabERN Coordination Office in Udine, Italy, providing administrative infrastructure for the network.
• CTX AlliancemajorStrategic or Co-development PartnerPartnership for Cerebrotendinous Xanthomatosis (CTX) disease awareness and research. The CTX Alliance hosts international workshops (Jerusalem 2023, Kyoto 2025) and collaborates with MetabERN on patient care initiatives.
• Society for the Study of Inborn Errors of Metabolism (SSIEM)majorGTM or Marketing PartnerAnnual symposium collaboration. MetabERN participates in and promotes the SSIEM Annual Symposium, with CTX International Scientific Meeting held as satellite to SSIEM 2023.
• SIMMESN (Italian Society for Study of Hereditary Metabolic Diseases)majorStrategic or Co-development PartnerCollaboration on surveys and diagnostic activities for metabolic disorders. Joint survey on diagnostic and monitoring activities for patients with metabolic disorders.
• Metabolic Support UKmajorStrategic or Co-development PartnerUK-based patient organisation collaborating with MetabERN on patient representation and campaigns such as 'Think Ammonia!'
• Nataliya Foundation & FAST BulgariaminorStrategic or Co-development PartnerPatient representative organisations within MetabERN for neuromodulators and small molecules disorders subnetwork.
• Spanish Association of GSD Patients (AEEG)majorStrategic or Co-development PartnerPatient organisation member of MetabERN board of patient organisations. Organised XVI International Glycogen Storage Disease Conference 2025 in Getafe.
• Jenny Mossler Rockström FoundationminorStrategic or Co-development PartnerPatient representative organisation within MetabERN for Smith-Lemli-Opitz syndrome (SLOS), collaborating on SLOS Natural History project.
• Other ERNs (European Reference Networks)majorStrategic or Co-development PartnerCollaboration with other ERNs including Endo-ERN on joint webinars and activities. Part of 24 ERNs launched by EU in 2017.
• Recordati Rare Diseases FoundationminorGTM or Marketing PartnerFoundation organising educational courses on inherited metabolic diseases with MetabERN participation (e.g., Newborn Screening course in Amsterdam 2026).

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Society for the Study of Inborn Errors of Metabolism (SSIEM): Long-established international scientific society for inherited metabolic disease research and education. MetabERN collaborates with SSIEM on its annual symposium. Comparable in addressing the same clinical community but operates as a professional society rather than a care coordination network.

Direct peers

• EuroBloodNet (ERN for rare haematological diseases): European Reference Network for rare haematological diseases. Direct ERN peer with identical EU institutional setup, multi-country network model, and CPMS-based virtual consultation infrastructure.
• Orphanet: European reference portal for rare diseases and orphan drugs, providing disease classifications, prevalence data, and expert centre listings. Peer in the rare disease knowledge infrastructure space, with overlapping purpose around rare disease expertise aggregation in Europe.
• EURORDIS (Rare Diseases Europe): European umbrella organisation for rare disease patient organisations. Peer in advocacy, patient organisation coordination, and rare disease policy across Europe—engages the same patient community MetabERN serves through its Patient Board.
• ERN-RND (ERN for rare neurological diseases): European Reference Network for rare neurological diseases. Sister ERN with the same institutional positioning, multi-country coverage, and rare disease coordination mandate.
• Endo-ERN: European Reference Network for rare endocrine conditions. Direct structural peer—same EU ERN programme, same coordination model, same CPMS platform, same 28-country footprint. MetabERN already collaborates with Endo-ERN on joint webinars and activities.
• EpiCARE (ERN for rare epilepsies): European Reference Network for rare and complex epilepsies. Same ERN programme structure, governance, funding mechanism, and CPMS infrastructure as MetabERN. Comparable in scope (multi-country rare disease network) and operational model.

Emerging players

• RD-CODE (Rare Disease Coding): EU-funded initiative for standardising rare disease coding across European healthcare systems. Peer in the rare disease data interoperability space—complementary to MetabERN's CPMS and U-IMD registry work.
• SIMMESN (Italian Society for Study of Hereditary Metabolic Diseases): Italian national scientific society for hereditary metabolic diseases. Peer at national level—MetabERN already partners with SIMMESN on joint diagnostic and monitoring surveys, making them a complementary national counterpart.

Others

• Orphan Drug Development Centre, Cambridge: Adjacent orphan drug and rare disease therapy development organisation. Thematically related to MetabERN through shared focus on rare disease treatment pathways, though operating in drug development rather than care coordination.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xbsky.app/profile/ernmetabern.bsky.social
• YouTubeyoutube.com/channel/UCqAjmyTVIUyDm_WT2ZT-m-g
• Facebookfacebook.com/MetabERN
• LinkedInlinkedin.com/company/metab_ern

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MetabERN